Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
about
Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient managementTreatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab.The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACTPharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancyChronic lymphocytic leukemia: planning for an aging populationThe combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaBendamustine: safety and efficacy in the management of indolent non-hodgkins lymphomaTreatment of chronic lymphocytic leukemia with bendamustine in an HIV-infected patient on antiretroviral therapy: a case report and review of the literatureBendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphomaBendamustine associated with irreversible ascending paralysisSynthesis and Antiproliferative Activities of Benzimidazole-Based Sulfide and Sulfoxide DerivativesDemographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study.Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party.Determination of Bendamustine in Human Plasma and Urine by LC-FL Methods: Application in a Drug MonitoringA Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events.Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.Recurrent or refractory primary central nervous lymphoma: therapeutic considerations.Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateBendamustine associated immune suppression and infections during therapy of hematological malignancies.Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials.Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study.Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine.A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).Bendamustine for non-Hodgkin lymphoma. Interview by Louise Rishton.Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
P2860
Q27002428-3944A850-10AA-42A7-B566-6024808206CAQ33394623-86E28095-3706-4CCB-ACB5-617F29B8DFEDQ33410064-19643ABB-EF6B-4EBC-A235-D1CBA50D35E9Q33425372-A7DA40CE-BCE3-4281-B7B8-80DF3738E904Q34322781-D82CEB1B-4687-4832-B7C2-39ED469168E0Q34560909-98DDCCF6-6411-4AFF-9785-03F9B257C6A7Q34707136-44C48ACD-D25E-495A-939B-128BF5681EC2Q35052538-0A25B012-973A-40EF-BD46-04E53BEB66E1Q35841817-CE77FD70-F753-43AA-BF5A-E1BDCD20B9B4Q35917095-2B59A658-CD51-4D41-B27A-A28B333F5A0AQ36000197-42F70A89-B969-477D-8A7F-BDC637EB9789Q36692070-8D3DA095-8C1E-4CFC-B30B-C2A24BCDD091Q36820914-313C8F3A-8F3A-4EC6-8C43-72C341F1430FQ36883352-8C19A903-B6F2-448D-8ADE-245043D08E20Q36967098-E12D5B9D-E084-45E1-A5F6-37A57DFF1BF3Q37059359-07DC52BF-51FA-480C-B059-51874A977818Q37577645-79E21925-1B00-427F-900F-CAEBA59350A0Q37788236-FB9224D0-21E5-46F4-813C-6EE7375EA859Q38040846-4DDF341C-134B-4239-B2AA-184236AC6CAAQ38140000-FDF7AB70-28B2-415D-BC98-69EA38DBCE07Q38152510-59E53A16-D7AB-4FEE-89B2-D8A2123D3ABBQ38548134-19893FAD-2146-4105-B370-9EB120D20BBCQ38642648-2A32A667-9127-4A82-B2A7-C3AAE6FFF6D9Q38676858-9DC599A1-69EC-4E89-BC7C-6DBCF3660226Q38920650-BE571FD1-C599-432A-B9C0-8A8D9B5153C8Q38979354-3E1DFB92-71D5-42D3-AF86-A3611539FA3FQ39005626-710352E3-BF81-485B-9297-502D12D0C0B7Q40095723-2A0AA7AB-BA37-47A6-8AD8-CD01479365DEQ40736899-026FEFA5-EE52-44E3-A54C-FC32264CEBCDQ41257177-C31811B9-0BD5-4A48-B448-C9D3F91D00DDQ41362824-A7AE922C-63DB-458A-BDE0-7F51FE431E12Q41418657-4C88A5CE-F81E-4839-817F-165FBFA23E07Q43584641-4D026C7E-81F9-4DCD-8BFE-53ECF1B128F2Q44098314-F519DAF7-3A7E-48A4-B663-C0C8073067F0Q44773928-A585656E-2DAB-438A-A1A6-2B82DFC41726Q45099661-D4E085EC-987C-48CC-A050-AD588C90F497Q47248893-04507A45-3CC3-44FA-89B4-B58B007AB42BQ50187344-A2F6490C-2BD3-4D86-814A-874E93B4910BQ51544428-F81FD2B0-C277-40A4-99A4-788A8CF81133Q52895479-F6AC343A-310F-433A-B6CF-8467F0FD02D1
P2860
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Optimal use of bendamustine in ...... international consensus panel.
@en
Optimal use of bendamustine in ...... international consensus panel.
@nl
type
label
Optimal use of bendamustine in ...... international consensus panel.
@en
Optimal use of bendamustine in ...... international consensus panel.
@nl
prefLabel
Optimal use of bendamustine in ...... international consensus panel.
@en
Optimal use of bendamustine in ...... international consensus panel.
@nl
P2093
P356
P1476
Optimal use of bendamustine in ...... international consensus panel.
@en
P2093
Angelika Pieper
Bruce D Cheson
Dieter Hoelzer
John Gribben
Jonathan Friedberg
Marco Montillo
Martin Dreyling
Mathias Rummel
Stefan Knop
P356
10.3816/CLML.2010.N.002
P407
P577
2010-02-01T00:00:00Z